Suppr超能文献

通过半胱氨酸反应化学对E3泛素连接酶结合的化学特性分析

Chemical Specification of E3 Ubiquitin Ligase Engagement by Cysteine-Reactive Chemistry.

作者信息

Sarott Roman C, You Inchul, Li Yen-Der, Toenjes Sean T, Donovan Katherine A, Seo Pooreum, Ordonez Martha, Byun Woong Sub, Hassan Muhammad Murtaza, Wachter Franziska, Chouchani Edward T, Słabicki Mikołaj, Fischer Eric S, Ebert Benjamin L, Hinshaw Stephen M, Gray Nathanael S

机构信息

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.

Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, United States.

出版信息

J Am Chem Soc. 2023 Oct 11;145(40):21937-21944. doi: 10.1021/jacs.3c06622. Epub 2023 Sep 28.

Abstract

Targeted protein degradation relies on small molecules that induce new protein-protein interactions between targets and the cellular protein degradation machinery. Most of these small molecules feature specific ligands for ubiquitin ligases. Recently, the attachment of cysteine-reactive chemical groups to pre-existing small molecule inhibitors has been shown to drive specific target degradation. We demonstrate here that different cysteine-reactive groups can specify target degradation via distinct ubiquitin ligases. By focusing on the bromodomain ligand JQ1, we identify cysteine-reactive functional groups that drive BRD4 degradation by either DCAF16 or DCAF11. Unlike proteolysis-targeting chimeric molecules (PROTACs), the new compounds use a single small molecule ligand with a well-positioned cysteine-reactive group to induce protein degradation. The finding that nearly identical compounds can engage multiple ubiquitination pathways suggests that targeting cellular pathways that search for and eliminate chemically reactive proteins is a feasible avenue for converting existing small molecule drugs into protein degrader molecules.

摘要

靶向蛋白质降解依赖于能够诱导靶标与细胞蛋白质降解机制之间形成新的蛋白质-蛋白质相互作用的小分子。这些小分子大多具有针对泛素连接酶的特异性配体。最近,已证明将半胱氨酸反应性化学基团连接到现有的小分子抑制剂上可驱动特定靶标的降解。我们在此证明,不同的半胱氨酸反应性基团可通过不同的泛素连接酶来指定靶标的降解。通过聚焦于溴结构域配体JQ1,我们鉴定出了可通过DCAF16或DCAF11驱动BRD4降解的半胱氨酸反应性功能基团。与蛋白酶靶向嵌合分子(PROTAC)不同,新化合物使用具有定位良好的半胱氨酸反应性基团的单个小分子配体来诱导蛋白质降解。几乎相同的化合物可参与多种泛素化途径这一发现表明,靶向寻找并消除化学反应性蛋白质的细胞途径是将现有小分子药物转化为蛋白质降解分子的可行途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验